Cargando…

Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer

BACKGROUND: Urothelial bladder cancer is most frequently diagnosed at the non-muscle-invasive stage (NMIBC). However, recurrences and interventions for intermediate and high-risk NMIBC patients impact the quality of life. Biomarkers for patient stratification could help to avoid unnecessary interven...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerzeli, Iliana K., Kostakis, Alexandros, Türker, Polat, Malmström, Per-Uno, Hemdan, Tammer, Mezheyeuski, Artur, Ward, Douglas G., Bryan, Richard T., Segersten, Ulrika, Lord, Martin, Mangsbo, Sara M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311740/
https://www.ncbi.nlm.nih.gov/pubmed/37391708
http://dx.doi.org/10.1186/s12885-023-11100-0
_version_ 1785066804023918592
author Kerzeli, Iliana K.
Kostakis, Alexandros
Türker, Polat
Malmström, Per-Uno
Hemdan, Tammer
Mezheyeuski, Artur
Ward, Douglas G.
Bryan, Richard T.
Segersten, Ulrika
Lord, Martin
Mangsbo, Sara M.
author_facet Kerzeli, Iliana K.
Kostakis, Alexandros
Türker, Polat
Malmström, Per-Uno
Hemdan, Tammer
Mezheyeuski, Artur
Ward, Douglas G.
Bryan, Richard T.
Segersten, Ulrika
Lord, Martin
Mangsbo, Sara M.
author_sort Kerzeli, Iliana K.
collection PubMed
description BACKGROUND: Urothelial bladder cancer is most frequently diagnosed at the non-muscle-invasive stage (NMIBC). However, recurrences and interventions for intermediate and high-risk NMIBC patients impact the quality of life. Biomarkers for patient stratification could help to avoid unnecessary interventions whilst indicating aggressive measures when required. METHODS: In this study, immuno-oncology focused, multiplexed proximity extension assays were utilised to analyse plasma (n = 90) and urine (n = 40) samples from 90 newly-diagnosed and treatment-naïve bladder cancer patients. Public single-cell RNA-sequencing and microarray data from patient tumour tissues and murine OH-BBN-induced urothelial carcinomas were also explored to further corroborate the proteomic findings. RESULTS: Plasma from muscle-invasive, urothelial bladder cancer patients displayed higher levels of MMP7 (p = 0.028) and CCL23 (p = 0.03) compared to NMIBC patients, whereas urine displayed higher levels of CD27 (p = 0.044) and CD40 (p = 0.04) in the NMIBC group by two-sided Wilcoxon rank-sum tests. Random forest survival and multivariable regression analyses identified increased MMP12 plasma levels as an independent marker (p < 0.001) associated with shorter overall survival (HR = 1.8, p < 0.001, 95% CI:1.3–2.5); this finding was validated in an independent patient OLINK cohort, but could not be established using a transcriptomic microarray dataset. Single-cell transcriptomics analyses indicated tumour-infiltrating macrophages as a putative source of MMP12. CONCLUSIONS: The measurable levels of tumour-localised, immune-cell-derived MMP12 in blood suggest MMP12 as an important biomarker that could complement histopathology-based risk stratification. As MMP12 stems from infiltrating immune cells rather than the tumor cells themselves, analyses performed on tissue biopsy material risk a biased selection of biomarkers produced by the tumour, while ignoring the surrounding microenvironment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11100-0.
format Online
Article
Text
id pubmed-10311740
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103117402023-07-01 Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer Kerzeli, Iliana K. Kostakis, Alexandros Türker, Polat Malmström, Per-Uno Hemdan, Tammer Mezheyeuski, Artur Ward, Douglas G. Bryan, Richard T. Segersten, Ulrika Lord, Martin Mangsbo, Sara M. BMC Cancer Research BACKGROUND: Urothelial bladder cancer is most frequently diagnosed at the non-muscle-invasive stage (NMIBC). However, recurrences and interventions for intermediate and high-risk NMIBC patients impact the quality of life. Biomarkers for patient stratification could help to avoid unnecessary interventions whilst indicating aggressive measures when required. METHODS: In this study, immuno-oncology focused, multiplexed proximity extension assays were utilised to analyse plasma (n = 90) and urine (n = 40) samples from 90 newly-diagnosed and treatment-naïve bladder cancer patients. Public single-cell RNA-sequencing and microarray data from patient tumour tissues and murine OH-BBN-induced urothelial carcinomas were also explored to further corroborate the proteomic findings. RESULTS: Plasma from muscle-invasive, urothelial bladder cancer patients displayed higher levels of MMP7 (p = 0.028) and CCL23 (p = 0.03) compared to NMIBC patients, whereas urine displayed higher levels of CD27 (p = 0.044) and CD40 (p = 0.04) in the NMIBC group by two-sided Wilcoxon rank-sum tests. Random forest survival and multivariable regression analyses identified increased MMP12 plasma levels as an independent marker (p < 0.001) associated with shorter overall survival (HR = 1.8, p < 0.001, 95% CI:1.3–2.5); this finding was validated in an independent patient OLINK cohort, but could not be established using a transcriptomic microarray dataset. Single-cell transcriptomics analyses indicated tumour-infiltrating macrophages as a putative source of MMP12. CONCLUSIONS: The measurable levels of tumour-localised, immune-cell-derived MMP12 in blood suggest MMP12 as an important biomarker that could complement histopathology-based risk stratification. As MMP12 stems from infiltrating immune cells rather than the tumor cells themselves, analyses performed on tissue biopsy material risk a biased selection of biomarkers produced by the tumour, while ignoring the surrounding microenvironment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11100-0. BioMed Central 2023-06-30 /pmc/articles/PMC10311740/ /pubmed/37391708 http://dx.doi.org/10.1186/s12885-023-11100-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kerzeli, Iliana K.
Kostakis, Alexandros
Türker, Polat
Malmström, Per-Uno
Hemdan, Tammer
Mezheyeuski, Artur
Ward, Douglas G.
Bryan, Richard T.
Segersten, Ulrika
Lord, Martin
Mangsbo, Sara M.
Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer
title Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer
title_full Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer
title_fullStr Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer
title_full_unstemmed Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer
title_short Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer
title_sort elevated levels of mmp12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311740/
https://www.ncbi.nlm.nih.gov/pubmed/37391708
http://dx.doi.org/10.1186/s12885-023-11100-0
work_keys_str_mv AT kerzeliilianak elevatedlevelsofmmp12sourcedfrommacrophagesareassociatedwithpoorprognosisinurothelialbladdercancer
AT kostakisalexandros elevatedlevelsofmmp12sourcedfrommacrophagesareassociatedwithpoorprognosisinurothelialbladdercancer
AT turkerpolat elevatedlevelsofmmp12sourcedfrommacrophagesareassociatedwithpoorprognosisinurothelialbladdercancer
AT malmstromperuno elevatedlevelsofmmp12sourcedfrommacrophagesareassociatedwithpoorprognosisinurothelialbladdercancer
AT hemdantammer elevatedlevelsofmmp12sourcedfrommacrophagesareassociatedwithpoorprognosisinurothelialbladdercancer
AT mezheyeuskiartur elevatedlevelsofmmp12sourcedfrommacrophagesareassociatedwithpoorprognosisinurothelialbladdercancer
AT warddouglasg elevatedlevelsofmmp12sourcedfrommacrophagesareassociatedwithpoorprognosisinurothelialbladdercancer
AT bryanrichardt elevatedlevelsofmmp12sourcedfrommacrophagesareassociatedwithpoorprognosisinurothelialbladdercancer
AT segerstenulrika elevatedlevelsofmmp12sourcedfrommacrophagesareassociatedwithpoorprognosisinurothelialbladdercancer
AT lordmartin elevatedlevelsofmmp12sourcedfrommacrophagesareassociatedwithpoorprognosisinurothelialbladdercancer
AT mangsbosaram elevatedlevelsofmmp12sourcedfrommacrophagesareassociatedwithpoorprognosisinurothelialbladdercancer